Hydrochloric Acid → HCID 86700870, 화합물
반응식
[CH:1]1([C:5]2[O:9][C:8]([NH:10][C:11]3[CH:12]=[N:13][C:14]([C:17]4[CH:22]=[CH:21][C:20]([C:23]56[CH2:30][CH2:29][C:26]([CH:31]=[CH:32][O:33]C)([CH2:27][CH2:28]5)[CH2:25][O:24]6)=[CH:19][CH:18]=4)=[CH:15][CH:16]=3)=[N:7][N:6]=2)[CH2:4][CH2:3][CH2:2]1.Cl>O1CCCC1>[CH:1]1([C:5]2[O:9][C:8]([NH:10][C:11]3[CH:16]=[CH:15][C:14]([C:17]4[CH:22]=[CH:21][C:20]([C:23]56[CH2:28][CH2:27][C:26]([CH2:31][CH:32]=[O:33])([CH2:29][CH2:30]5)[CH2:25][O:24]6)=[CH:19][CH:18]=4)=[N:13][CH:12]=3)=[N:7][N:6]=2)[CH2:4][CH2:3][CH2:2]1참가 물질
4
실험 절차
To a stirred solution of 5-cyclobutyl-N-(6-(4-(4-(2-methoxyvinyl)-2-oxabicyclo[2.2.2]octan-1-yl)phenyl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine (10 mg, 0.022 mmol) in tetrahydrofuran (1 ml) at room temperature, was added 1N aqueous HCl solution (0.436 ml, 0.436 mmol). The reaction mixture was stirred for 1 h at room temperature. Most of solvent was removed by evaporation under vacuum, and the residue was purified by flash chromotography to afford 2-(1-(4-(5-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)acetaldehyde intermediate.